Dr. Reddy's Semaglutide Launch in Canada Faces Regulatory Delay Following Compliance Notice
核心洞察
Dr. Reddy's Laboratories received a notice of non-compliance from Canada's Pharmaceutical Drugs Directorate (搜索) regarding its semaglutide generic drug submission, delaying the anticipated launch.
The company's stock dropped over 5% following the regulatory setback, which affects plans to capitalize on the $1.6 billion Canadian semaglutide market when patents expire in January 2025.
Despite the delay, Dr. Reddy's remains confident in its product quality and plans to launch semaglutide across 87 countries, with initial manufacturing capacity of 12 million pens annually.
Dr. Reddy's Laboratories has encountered a significant regulatory hurdle in its plans to launch a generic version of the blockbuster weight-loss and diabetes (搜索) drug semaglutide in Canada. The Pharmaceutical Drugs Directorate (搜索) of Canada issued a notice of non-compliance (NON) regarding the company's abbreviated new drug submission (ANDS), potentially delaying what was expected to be a lucrative first-to-market opportunity.
The regulatory setback sent Dr. Reddy's share prices plunging more than 5% in early trading on the BSE on Thursday, October 30, 2025. The timing is particularly challenging for the Indian pharmaceutical giant, which is betting heavily on new product launches to offset declining U.S. revenue from its generic cancer (搜索) drug Lenalidomide, the generic version of Revlimid.
Regulatory Response and Timeline
"The NON outlines requests for additional information and clarifications on specific aspects of the submission. We will submit a response well within the stipulated time period," Dr. Reddy's stated in a regulatory filing on Wednesday evening, October 29, 2025. The company emphasized its confidence in "the quality, safety and comparability of the proposed product" and commitment to making "this important therapy available to patients in Canada and other markets at the earliest."
Analysts at Emkay Research (搜索) project a minimum 6-month delay based on historical NON patterns. "If Dr. Reddy's responds by December 2025, we anticipate an approval by the end of 1QFY27, in the best case scenario," the research firm noted.
Market Opportunity and Competition
The stakes are substantial for Dr. Reddy's semaglutide ambitions. The Canadian market for semaglutide, currently dominated by Novo Nordisk's Ozempic brand, represents $1.6 billion in annual sales. The drug is set to go off-patent on January 4 in Canada, creating a significant generic opportunity.
According to CFO M.V. Narasimham, Dr. Reddy's was the first generic company to file an application with Health Canada for semaglutide approval. Only four generic companies have filed applications so far, including Sandoz, Apotex (搜索), and one other unnamed competitor. "Going by the current filing, ours will be the first generic launch in Canada," Narasimham told Informist in a July interview.
The company's first-mover advantage could translate into substantial revenues. Even with mandatory 25% discounting under Canadian regulations, Dr. Reddy's projects potential sales of $300-400 million, depending on pricing and market uptake. "Even if the price reduces to half of the current pricing in Canada, the company is confident of achieving $300 million in revenue in the initial phase," Narasimham explained.
Global Launch Strategy
Beyond Canada, Dr. Reddy's has ambitious plans for semaglutide across multiple markets. The company intends to launch the GLP-1 (搜索) agonist in more than 80 countries, with specific timelines including Brazil by May, India around March, and Turkey at a later date. A Subject Expert Committee of India's Central Drugs Standard Control Organisation (搜索) (CDSCO) has already recommended approval for the semaglutide injection.
However, the Indian launch must wait until patent expiry in March 2026. The company expects intense competition in India, with several companies preparing their own versions of the drug.
Manufacturing and Development
Dr. Reddy's has invested significantly in both active pharmaceutical ingredient (API) production and fill-finish capacity for semaglutide. One of the company's units (CTO-6) manufactures the API, while initial capacity planning targets 12 million pens annually, with plans to scale to 50 million pens.
The company has also established a contract manufacturing partnership with Bengaluru-based Stelis Biopharma (搜索) for initial production phases, while transitioning manufacturing to its FTO-11 facility near Visakhapatnam for long-term production.
Patent Litigation Concerns
A critical factor in Dr. Reddy's launch timeline involves ongoing patent litigation with Novo Nordisk. The Danish pharmaceutical company has filed a patent infringement lawsuit that is currently before the Delhi High Court, with judgment pending. Dr. Reddy's leadership maintains that the company "believes the patent is invalid," but the court's decision will be crucial for the generic launch strategy.
Broader GLP-1 Portfolio
Semaglutide represents just the beginning of Dr. Reddy's GLP-1 (搜索) ambitions. The company has identified approximately 40 peptides for development, either independently or through partnerships, over the next several years. Semaglutide and liraglutide are expected to be the first products to reach markets globally, excluding the United States where patent protection extends until 2032.
The company plans to launch a total of 26 products under the GLP-1 (搜索) category over the next decade, positioning itself as a significant player in this rapidly growing therapeutic area that addresses both diabetes (搜索) and obesity (搜索) treatment needs.